Chemomab Therapeutics reports new clinical data at EASL 2025 on nebokitug

Chemomab Therapeutics (CMMB) reported data from two study abstracts that will be presented as posters at EASL 2025, the Annual Congress of the European Association for the Study of the Liver, that will be held May 7-10, 2025, in Amsterdam, the Netherlands. Comprehensive proteomic analyses of 3,000 circulating proteins in patient samples from the Phase 2 SPRING trial in patients with PSC showed that nebokitug-treated patients exhibited significant and dose-dependent changes in multiple proteins, including those playing a key role in fibrosis, immune cell recruitment and inflammation. The analysis provided new insights into PSC disease-related pathways and additional biological evidence of the clinical activity of nebokitug. Nebokitug-treated patients showed downregulation of biological processes related to fibrosis and inflammation, such as cell-cell adhesion and extracellular matrix organization, as well as to molecular functions including binding of growth factors and integrins.